ORIGINAL ARTICLE

Beneficial effect of a polyphenol-rich diet on cardiovascular risk: a randomised control trial

Rebecca L Noad,1,2 Ciara Rooney,1 Damian McCall,2 Ian S Young,1,2 David McCance,2 Michelle C McKinley,1,3 Jayne V Woodside,1,3 Pascal P McKeown1,2

ABSTRACT

Objectives There is previous epidemiological evidence that intake of polyphenol-rich foods has been associated with reduced cardiovascular disease risk. We aimed to investigate the effect of increasing dietary polyphenol intake on microvascular function in hypertensive participants.

Methods All participants completed a 4-week run-in phase, consuming <2 portions of fruit and vegetables (F&V) daily and avoiding berries and dark chocolate. Subjects were then randomised to continue with the low-polyphenol diet for 8 weeks or to consume a high-polyphenol diet of six portions F&V (including one portion of berries/day and 50 g of dark chocolate). Endothelium-dependent (acetylcholine, ACh) and endothelium-independent (sodium nitroprusside) vasodilator responses were assessed by venous occlusion plethysmography. Compliance with the intervention was measured using food diaries and biochemical markers.

Results Final analysis of the primary endpoint was conducted on 92 participants. Between-group comparison of change in maximum % response to ACh revealed a significant improvement in the high-polyphenol group (p<0.001). There was a significantly larger increase in vitamin C, carotenoids and epicatechin in the high-polyphenol group (between-group difference p<0.001; p<0.001; p=0.008, respectively).

Conclusions This study has shown that increasing the polyphenol content of the diet via consumption of F&V, berries and dark chocolate results in a significant improvement in an established marker of cardiovascular risk in hypertensive participants.

Trial registration number NCT01319786.

Previous epidemiological and intervention study evidence suggests that increasing fruit and vegetable (F&V) consumption improves cardiovascular disease (CVD) risk.1 A previous dietary intervention by McCall and colleagues in hypertensive subjects (Fruit and Vegetable Randomised Intervention Trial, FAVRIT) demonstrated a 6% improvement in endothelium-dependent vasodilation, as a measure of vascular function, for every portion/day increase in fruit or vegetables.2 Post hoc analysis of the FAVRIT data indicated that berry consumption was the class of fruit most associated with an improvement in microvascular function. It was hypothesised that this could be attributed to berries with high polyphenol content. Observational evidence to date indicates that polyphenol-rich foods, in particular berries3–4 and dark chocolate,5–7 may influence CVD risk. However, there are few polyphenol-specific dietary intervention studies of sufficiently robust design that assess the effect of polyphenol-rich foods on microvascular function.

The aim of the Polyphenol Intervention Trial (PPhIT) was to investigate if increasing overall polyphenol dietary intake (through the consumption of six portions of F&V/day including one portion of berries and 50 g of dark chocolate) would affect microvascular function, measured by forearm blood flow (FBF) responses to an endothelium-dependent vasodilator, and also have a beneficial effect on a range of other markers of CVD risk, such as systolic blood pressure (SBP) and lipid profile, in patients with hypertension.

The FBF measure of microvascular function was chosen as the primary endpoint, due to its use in previous dietary interventions, including the FAVRIT study,2 and because responses to endothelium-dependent vasodilators such as acetylcholine (ACh) have previously been shown to be reduced in individuals with hypertension.3–9 FBF responses to ACh have also been independently associated with cardiovascular morbidity in hypertensive patients10 and, in those with established CVD, improved FBF responses were significantly correlated with improved survival after acute coronary syndrome.11

Participants with hypertension were chosen because they represent a common cardiovascular risk cohort in whom modification of diet is feasible. There are several studies linking hypertension with reduced response to endothelium-dependent vasodilators.8–9 In addition, the current European Society of Cardiology guidelines for management of hypertension endorse increasing F&V intake to five portions per day, based on studies of a Mediterranean diet,13 making it a relevant population in which to conduct a randomised controlled dietary intervention trial.14

METHODS

Overview of study and endpoints

The study used a 12-week randomised controlled, single-blinded dietary intervention design. The study commenced with a four-week ‘run-in phase’ for all participants, during which they were asked to consume two portions or less of F&V and to exclude berries and dark chocolate (low-polyphenol diet). At the end of this period, subjects were randomised to continue with the above low-polyphenol diet for a further 8-week ‘intervention period’ or to consume a high-polyphenol diet of six portions F&V (including one portion of berries per day) and 50 g of dark chocolate per day (figure 1).

The primary endpoint was between-group change in maximum FBF response to the endothelium-dependent vasodilator, ACh. Secondary endpoints included between-group change in self-reported polyphenol-rich food intake, between-group change in biochemical markers of nutritional status and between-group change in SBP and lipid profile. The study had ethical approval from the Office of Research Ethics Committee Northern Ireland (ref 10/NIR03/39) and was registered at ClinicalTrials.gov (ref NCT01319786).

Inclusion criteria
Participants aged 40–65 years, with documented grade I (140–159/90–99 mm Hg) or grade II (160–179/100–109 mm Hg) hypertension, were eligible. Potential participants had brachial blood pressure (BP) measured after 10 min rest using an Omron M5-1 automatic BP monitor (Omron Healthcare, Hoofdorp, Netherlands) from the dominant arm. Three consecutive measurements were recorded and a summary BP calculated from the second and third readings.

Exclusion criteria
Exclusion criteria included diabetes mellitus, acute coronary syndrome or transient ischaemic attack within 3 months, pregnancy or lactation, fasting triglyceride concentration >4 mmol/L, alcohol consumption (>28 units/week for men and >21 units/week for women), oral anticoagulant therapy or antioxidant supplements, dietary restrictions that would limit ability to comply with the study diets and body mass index (BMI) >35 kg/m² with an impalpable brachial artery.

Randomisation
Participants’ baseline habitual polyphenol dietary content was measured at the screening visit using a modified version of the food frequency questionnaire developed for the European Cardiac risk factors and prevention

Figure 1  Overview of study design. F&V, fruit and vegetables.
Prospective Investigation of Cancer study. Eligible participants were stratified into high-polyphenol or low-polyphenol consumers and then block randomised using a random-number generator (http://www.randomization.com, block size n=6). The investigator performing FBF assessment (RLN) and staff conducting laboratory analysis were blinded to diet allocation.

**Dietary intervention**

Participants received individual nutrition consultations with a nutrition researcher (CR), as well as literature regarding portion sizes based on the UK Food Standard Agency guidelines (http://www.eatwell.gov.uk). All participants in the high-polyphenol diet had a self-selected weekly delivery of F&V and dark chocolate (Lindt 70% cocoa) free of charge to their homes from a local supermarket. Each participant was also contacted by telephone at weekly intervals. At each study visit, weight, hip and waist circumference were measured and questionnaires completed to quantify any change in level of physical activity.

**Measurement of compliance**

Dietary compliance was assessed using four-day food diaries on four occasions, two unannounced 24-h recalls and daily study food records completed by participants. Biochemical assessment of nutritional status included measurement of plasma vitamin C and carotenoids. To specifically monitor for dark chocolate consumption, urinary epicatechins were measured, as these represent one of the major polyphenols in cocoa.

**Assessment of vascular function**

Participants attended for assessments of microvascular function before and after the 8-week intervention period. Room temperature was maintained at 22°C–24°C. All testing was performed by a single investigator (RLN) who remained blinded to intervention phase dietary allocations throughout the study and during statistical analysis. Participants attended between 07:00 and 11:00 h, having fasted for at least 12 h and refrained from ingestion of caffeine, alcohol, nicotine or long-acting nitrate preparations.

Venous occlusion plethysmography was used to determine FBF during intra-arterial infusions of ACh and sodium nitroprusside (SNP), endothelium-dependent and endothelium-independent vasodilators, respectively. Each FBF study was conducted according to an established standard operating procedure within the facility. After infiltration with 1% lidocaine, a

![Figure 2](http://heart.bmj.com/content/102/13/1371)  
**Figure 2** CONSORT flow diagram summarising patient recruitment. FBF, forearm blood flow; hsCRP, highly sensitive C-reactive protein.
27-gauge sterile needle (Cooper’s Needle Works, Birmingham, UK) was inserted into the non-dominant brachial artery using an aseptic technique. At baseline and during vasodilator administration, plethysmographic measurements were made with electrically calibrated mercury-in-silastic strain gauges (PMS Instruments, Maidenhead, UK) in both the infused and non-infused limbs, to control for unexpected stimuli. Each strain gauge was attached to a Hokanson EC6 plethysmograph (PMS Instruments), which in turn was connected to a dedicated computer on which the Hokanson NIVP3 Dual Channel software (V.5.40, PMS Instruments) was installed. Initially saline was infused through the needle via an epidural catheter at a rate of 1 mL/min for at least 30 min, followed by incremental intra-arterial infusions of ACh (50, 100 and 200 nmol/min) and SNP (5, 10 and 20 nmol/min). Each concentration was infused for 5 min before five FBF readings were made during 7 s periods of venous occlusion separated by 20 s intervals.

Mean inflow curve gradients for each concentration of both infusions were calculated using NIVP3 software. This was performed for infused and control arms to yield flow rates in mL/100 mL forearm volume (ie, % change). Each participant formed for infused and control arms to yield infusions were calculated using NIVP3 software. This was performed for infused and control arms to yield flow rates in mL/100 mL forearm volume (ie, % change). Each participant’s responses were summarised by curves of % increase in infused:non-infused ratio against vasodilator dose. The summary measure used was maximum vasodilator response observed.

Laboratory analysis

Plasma vitamin C was measured on a FLUOstar Optima plate reader (BMG Labtech, Ortenberg, Germany) adapted from the method by Vuilleumier and Keck. Serum concentrations of six carotenoids (α-carotene, β-carotene, β-cryptoxanthin, lutein, lycopene and zeaxanthin) were measured by reverse-phase high-performance liquid chromatography (HPLC) as described by Craft. Fasting serum lipid profiles (total cholesterol, high-density lipoprotein and triglycerides) were assessed using standard enzymatic colorimetric assays on an automated Cobas 8000 Modular system biochemical analyser (Roche Diagnostics, West Sussex, UK).

Low-density lipoprotein (LDL) cholesterol was calculated using a standard Friedewald formula. Urine collected from the volunteers between evening meal and midnight the day before each study visit was analysed, including an enzymatic hydrolysis step, to quantify total epicatechin content using an Agilent Technologies 1100 series HPLC (Agilent Technologies, Stockport, UK) directly linked to a Waters Micromass Quatro Ultima Platinum API triple quadrupole mass spectrometer (Waters, Dublin, Ireland).

Statistical analysis and power calculation

Results are expressed as mean±SD for normally distributed continuous variables. Skewed variables were log-transformed and summarised as geometric mean and IQR, where appropriate. The principal analysis for each outcome variable was a between-group comparison of change using independent sample t tests or χ² test. These analyses were confirmed using analysis of covariance using postintervention values as the outcome variable and adjusting for preintervention values. Within-group comparisons were performed using paired samples t tests. Univariate linear regression analysis was also used to further examine vascular function results. All statistical analyses were performed using SPSS V20 (SPSS, Chicago, Illinois, USA).

The power calculation was based on data collected as part of the FAVRT study. To detect a 33% difference (the difference detected in FAVRT) between groups in this variable with 90% power using a two-tailed test at the 5% significance level would require 50 participants per group. Participants who were found to have an elevated highly sensitive C-reactive protein (hsCRP) >10 mg/L at any point in the study, indicating acute inflammation, were excluded from final analysis, in line with American Heart Association guidelines.

RESULTS

Summary of recruitment

The CONSORT recruitment summary is illustrated in figure 2. Overall, 155 individuals attended for screening. Of these, 51

Table 1  Pre–eight-week intervention period participant characteristics according to diet allocation

<table>
<thead>
<tr>
<th></th>
<th>Low polyphenol (n=47)</th>
<th>High polyphenol (n=46)</th>
<th>Between-group comparison p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)*</td>
<td>55.6 (6.8)</td>
<td>54.0 (6.7)</td>
<td>0.235</td>
</tr>
<tr>
<td>Male (%)†</td>
<td>28 (59.6)</td>
<td>22 (47.8)</td>
<td>0.301</td>
</tr>
<tr>
<td>Body mass index (kg/m²)*</td>
<td>29.8 (5.0)</td>
<td>31.6 (6.5)</td>
<td>0.148</td>
</tr>
<tr>
<td>Systolic blood pressure (mm Hg)*</td>
<td>141.7 (9.3)</td>
<td>140.6 (8.9)</td>
<td>0.589</td>
</tr>
<tr>
<td>Diastolic blood pressure (mm Hg)*</td>
<td>85.5 (6.9)</td>
<td>84.5 (7.6)</td>
<td>0.460</td>
</tr>
<tr>
<td>Current smoker (%)†</td>
<td>4 (8.5)</td>
<td>6 (13.0)</td>
<td>0.523</td>
</tr>
<tr>
<td>Former smoker (%)†</td>
<td>24 (51.1)</td>
<td>18 (39.1)</td>
<td>0.300</td>
</tr>
<tr>
<td>Antihypertensive therapy (%)†</td>
<td>37 (78.7)</td>
<td>36 (78.3)</td>
<td>0.999</td>
</tr>
<tr>
<td>Lipid-lowering therapy (%)†</td>
<td>21 (44.7)</td>
<td>19 (41.3)</td>
<td>0.825</td>
</tr>
<tr>
<td>Total cholesterol (mmol/L)*</td>
<td>5.2 (1.2)</td>
<td>5.8 (1.3)</td>
<td>0.020</td>
</tr>
<tr>
<td>HDL (mmol/L)*</td>
<td>1.4 (0.4)</td>
<td>1.4 (0.4)</td>
<td>0.568</td>
</tr>
<tr>
<td>LDL (mmol/L)*</td>
<td>4.2 (1.3)</td>
<td>4.7 (1.4)</td>
<td>0.038</td>
</tr>
<tr>
<td>Triglycerides (mmol/L)*</td>
<td>1.6 (1.0, 2.3)</td>
<td>1.6 (1.1, 2.1)</td>
<td>0.796</td>
</tr>
<tr>
<td>Total cholesterol/HDL ratio*</td>
<td>3.9 (1.3)</td>
<td>4.2 (1.2)</td>
<td>0.267</td>
</tr>
<tr>
<td>Max response ACh (infused:non-infused) (%)*§</td>
<td>123.9 (99.6)</td>
<td>109.1 (84.7)</td>
<td>0.447</td>
</tr>
<tr>
<td>Max response SNP (infused:non-infused) (%)*§</td>
<td>126.3 (120.4)</td>
<td>107.7 (70.1)</td>
<td>0.369</td>
</tr>
</tbody>
</table>

Bold figures signify significant p values.

*Normally distributed data summarised as mean (SD). Difference between groups assessed using independent samples t test.
†Categorical variables are summarised as n (%). Difference between groups assessed using χ² test.
‡Skewed data were logarithmically transformed and presented as geometric mean (IQR). Difference between groups assessed using independent samples t test.
§Based on 92 subjects due to missing data for one participant in low-polyphenol group.

ACh, acetylcholine; HDL, high-density lipoprotein; LDL, low-density lipoprotein; SNP, sodium nitroprusside.

### Table 2: Preintervention and postintervention period results of self-reported dietary intake and micronutrient concentrations by diet allocation

<table>
<thead>
<tr>
<th></th>
<th>Low polyphenol (n=47)</th>
<th></th>
<th>Within-group p value</th>
<th>High polyphenol (n=46)</th>
<th></th>
<th>Change</th>
<th>Within-group p value</th>
<th>Between-group p value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Pre</td>
<td>Post</td>
<td>Change</td>
<td>Pre</td>
<td>Post</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>F&amp;V intake</strong> †</td>
<td>1.38 (0.80)</td>
<td>1.25 (0.57)</td>
<td>−0.13 (−0.35 to 0.10)</td>
<td>1.40 (0.71)</td>
<td>6.82 (2.12)</td>
<td>5.42</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td><strong>Berries (portions/day)†‡</strong></td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>N/A</td>
<td>0</td>
<td>1.00</td>
<td>(0.80 to 1.25)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td><strong>Dark chocolate (g/day)†‡</strong></td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>N/A</td>
<td>0</td>
<td>50.0</td>
<td>(37.5 to 50.0)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td><strong>Epicatechin (nmol/mol crt)</strong></td>
<td>0.12 (0.20)</td>
<td>0.10 (0.12)</td>
<td>−0.02 (−0.08 to 0.06)</td>
<td>0.10 (0.30)</td>
<td>0.30 (0.29)</td>
<td>0.19</td>
<td>(0.07 to 0.31)</td>
<td>0.002</td>
</tr>
<tr>
<td><strong>Vitamin C (μmol/L)†§</strong></td>
<td>25.1 (18.3 to 52.3)</td>
<td>19.6 (11.8 to 48.9)</td>
<td>0.79 (0.63 to 0.96)</td>
<td>28.4 (18.6 to 57.5)</td>
<td>51.7 (43.9 to 68.6)</td>
<td>1.82</td>
<td>(1.34 to 7.25)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td><strong>Lutein (μmol/L)§</strong></td>
<td>0.16 (0.12 to 0.20)</td>
<td>0.15 (0.11 to 0.20)</td>
<td>0.98 (0.90 to 1.06)</td>
<td>0.595</td>
<td>0.15 (0.11 to 0.19)</td>
<td>0.20</td>
<td>(0.15 to 0.26)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td><strong>Zeaxanthin (μmol/L)§</strong></td>
<td>0.04 (0.03 to 0.05)</td>
<td>0.04 (0.03 to 0.05)</td>
<td>0.97 (0.91 to 1.03)</td>
<td>0.331</td>
<td>0.04 (0.03 to 0.05)</td>
<td>0.05</td>
<td>(0.04 to 0.06)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td><strong>β-Cryptoxanthin (μmol/L)§</strong></td>
<td>0.05 (0.04 to 0.08)</td>
<td>0.05 (0.03 to 0.08)</td>
<td>0.92 (0.83 to 1.03)</td>
<td>0.134</td>
<td>0.05 (0.04 to 0.07)</td>
<td>0.07</td>
<td>(0.05 to 0.10)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td><strong>α-Carotene (μmol/L)§</strong></td>
<td>0.12 (0.09 to 0.16)</td>
<td>0.11 (0.08 to 0.14)</td>
<td>0.90 (0.82 to 0.99)</td>
<td>0.037</td>
<td>0.12 (0.10 to 0.15)</td>
<td>0.14</td>
<td>(0.11 to 0.20)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td><strong>β-Carotene (μmol/L)§</strong></td>
<td>0.24 (0.15 to 0.36)</td>
<td>0.21 (0.14 to 0.32)</td>
<td>0.91 (0.82 to 1.01)</td>
<td>0.064</td>
<td>0.26 (0.19 to 0.36)</td>
<td>0.30</td>
<td>(0.23 to 0.42)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td><strong>Lycopene (μmol/L)§</strong></td>
<td>0.45 (0.33 to 0.69)</td>
<td>0.43 (0.33 to 0.58)</td>
<td>0.95 (0.85 to 1.06)</td>
<td>0.343</td>
<td>0.47 (0.38 to 0.66)</td>
<td>0.53</td>
<td>(0.41 to 0.69)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td><strong>Total carotenoids (μmol/L)§</strong></td>
<td>1.09 (0.84 to 1.47)</td>
<td>0.99 (0.75 to 1.34)</td>
<td>0.93 (0.86 to 1.09)</td>
<td>1.13 (0.91 to 1.36)</td>
<td>1.32 (1.06 to 1.67)</td>
<td>1.17</td>
<td>(1.06 to 1.29)</td>
<td>0.003</td>
</tr>
</tbody>
</table>

Bold figures signify significant p values.  
*Normally distributed variables at baseline were summarised as mean (SD). Within-group change assessed using paired samples t test and between-group differences in change assessed using independent samples t test.  
†Based on 92 patients due to incomplete food diary and insufficient Vitamin C sample in high-polyphenol group.  
‡Non-parametric data at baseline presented as median (IQR). Within-group change assessed using Wilcoxon signed-rank test and between-group differences in change calculated using Mann–Whitney U test.  
§Skewed variables were logarithmically transformed and baseline values summarised as geometric mean (IQR). Within-group change assessed using paired samples t test and between-group differences in change assessed using independent samples t test. Change expressed as median difference (IQR).  
F&V, fruit and vegetables; N/A, not applicable.
(33%) did not meet the inclusion criteria or were unable to participate. In total, 104 participants commenced the study; two withdrew during the washout period due to family or work reasons. At randomisation, 102 patients (51 per group) were allocated to either a high-polyphenol or low-polyphenol diet. There were three dropouts during the intervention phase: two from the high-polyphenol group due to personal reasons and a change in antihypertensive therapy, respectively, and one from the low-polyphenol group due to personal illness. Therefore, 99 participants completed the study between January 2010 and April 2013.

Of these, six had a recorded serum hsCRP > 10 mg/L at one or more time points during the study and were excluded from further analyses. Of the remaining 93 participants, there were missing postintervention plasma samples required for vitamin C analysis for one participant, one patient did not return a complete set of food diaries, and postintervention FBF studies had to be abandoned in another patient due to computer hardware issues on that visit. A full data set was therefore available on a total of 90 participants. Baseline results prior to entry to washout period are not shown.

Baseline characteristics
Baseline preintervention characteristics recorded after the 4-week run-in period are summarised in table 1. There were no significant differences between the two groups, with the exception of total cholesterol and LDL, which were both higher in the high-polyphenol group (p=0.020 and p=0.038, respectively).

Changes in measure of compliance
Results for self-reported polyphenol intake and micronutrients are summarised in table 2. Between-group change showed a significant increase in self-reported polyphenol intake in the high-polyphenol group compared with the low-polyphenol group (p<0.001 for all). There was also a significant between-group difference in change in micronutrient status: concentrations of urinary epicatechin (p<0.001), plasma vitamin C (p<0.001) and all serum carotenoids (with the exception of lycopene (p=0.098)) with a significantly larger increase in the high-polyphenol group compared with the low-polyphenol group.

Changes in markers of cardiovascular risk
There were no significant changes in BMI within (low-polyphenol group 29.8 kg/m² preintervention and 29.8 kg/m² postintervention (p=0.842), high-polyphenol group 31.6 kg/m² and 31.6 kg/m² post (p=0.961)) or between groups (p=0.897) during the intervention (table 3). There was a trend towards a larger decrease in SBP in the high-polyphenol group compared with the low-polyphenol group; this was of borderline statistical significance (p=0.059). Within-group analysis found that SBP decreased significantly within both the low-polyphenol (141.7

<table>
<thead>
<tr>
<th>Table 3</th>
<th>Preintervention and postintervention period results of cardiovascular risk assessments by diet allocation</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>High Polyphenol (n=47)</td>
</tr>
<tr>
<td>Max response to acetylcholine, infused:non-infused (%)*</td>
<td>136.7 (143.7)</td>
</tr>
<tr>
<td>Max response to sodium nitroprusside, infused:non-infused (%)*</td>
<td>141.7 (33.3)</td>
</tr>
<tr>
<td>Systolic blood pressure (mm Hg)*</td>
<td>143.9 (9.3)</td>
</tr>
<tr>
<td>Diastolic blood pressure (mm Hg)*</td>
<td>85.5 (6.9)</td>
</tr>
<tr>
<td>Body mass index (kg/m²)*</td>
<td>29.8 (5.0)</td>
</tr>
<tr>
<td>Total cholesterol (mmol/L)*</td>
<td>5.3 (1.0)</td>
</tr>
<tr>
<td>Low-density lipoprotein (mmol/L)*</td>
<td>1.4 (1.1)</td>
</tr>
<tr>
<td>Triglycerides (mmol/L)†</td>
<td>1.6 (0.9)</td>
</tr>
</tbody>
</table>

Bold figures signify significant p values. *Normally distributed variables at baseline were summarised as mean (SD). Within-group change assessed using paired samples t test, between-group difference in change assessed using independent samples t test. Change expressed as mean difference (95% CI). †Skewed variables were logarithmically transformed and baseline values summarised as geometric mean (IQR). Within-group change assessed using paired samples t test and between-group differences in change assessed using independent samples t test.
responses. The available prognostic association data suggest that improving endothelium-dependent FBF with a diet rich in polyphenol intake, and specifically including berries, could result in a significant improvement in endothelial-dependent responses. The available prognostic association data suggest that increasing endothelium-dependent FBF with a diet rich in polyphenols could potentially modify CVD risk. An effect due to displacement of other foods from participants’ diets cannot, however, be excluded.

There was a significant between-group change in reported F&V intake. Given that self-reported data are prone to reporting bias, independent confirmation was provided by biomarkers, including assessment of plasma vitamin C and a panel of serum carotenoids. This indicated good compliance with the dietary intervention. The epicatechin content of the dark chocolate provided to participants was not measured during this study. However, previous studies have measured epicatechin levels in the brand of dark chocolate used in this intervention. Using these data, the amount of dark chocolate provided would have delivered a dose of 35.7 mg epicatechin/day. Compliance with dark chocolate was demonstrated by a significant increase in evening meal to midnight urinary epicatechin levels detected on between-group testing. Urinary epicatechin use has been found to be superior to plasma epicatechin measurement as peak levels are detected 6–12 h postconsumption. The addition of dark chocolate to the regimen may have increased the palatability of the diet. Participant feedback showed a 90% approval rating for the overall diet, indicating that it was well tolerated.

There was a trend towards greater lowering in SBP within the high-polyphenol group compared with the low-polyphenol group (mean change: −9.1±12.4 mm Hg vs −4.8±8.7 mm Hg respectively, p=0.059) on between-group analysis. Both SBP and diastolic BP decreased significantly on within-group analysis. However, the decrease in BP in both active and control groups may represent ‘regression to the mean’, a phenomenon that has been described in previous BP studies. Few polyphenol dietary intervention trials have assessed SBP. Previous calculations estimate that 115 participants would be required per group to detect a 5 mm Hg change in SBP with 90% power; therefore, this study may have been underpowered to detect a difference in SBP between groups, and a type II error is possible.

Between-group testing demonstrated a significantly greater reduction in total cholesterol (p=0.042) and a trend for greater

**DISCUSSION**

The PPhIT study aimed to extend a previous dietary intervention (FAVIRT) that had been shown to improve microvascular function in hypertensive subjects. This study develops those findings by showing that increasing polyphenol content with the addition of berries and dark chocolate potentially has additional benefits on microvascular function and CVD risk. The ideal combination of polyphenol-rich foods for cardiovascular health remains under debate. It was hypothesised that this diet would provide increased benefits to cardiovascular health and, importantly, given its palatability, be easily adopted by the general public.

The primary endpoint of the PPhIT study was between-group change in maximum FBF response to the endothelium-dependent vasodilator, ACh. Between-group comparison showed that those subjects who received a high-polyphenol diet had a significantly greater improvement in maximum % response to ACh, compared with the low-polyphenol group (p=0.02). This suggests that increasing consumption of polyphenol-rich foods improves endothelium-dependent FBF response in hypertensive volunteers.

Therefore, the present findings indicate that increasing polyphenol intake, and specifically including berries, alongside consumption of a moderate portion of dark chocolate, could result in a significant improvement in endothelium-dependent responses. The available prognostic association data suggest that improving endothelium-dependent FBF with a diet rich in polyphenols could potentially modify CVD risk. An effect due to displacement of other foods from participants’ diets cannot, however, be excluded.

There was a significant between-group change in reported F&V intake. Given that self-reported data are prone to reporting bias, independent confirmation was provided by biomarkers, including assessment of plasma vitamin C and a panel of serum carotenoids. This indicated good compliance with the dietary intervention. The epicatechin content of the dark chocolate provided to participants was not measured during this study. However, previous studies have measured epicatechin levels in the brand of dark chocolate used in this intervention. Using these data, the amount of dark chocolate provided would have delivered a dose of 35.7 mg epicatechin/day. Compliance with dark chocolate was demonstrated by a significant increase in evening meal to midnight urinary epicatechin levels detected on between-group testing. Urinary epicatechin use has been found to be superior to plasma epicatechin measurement as peak levels are detected 6–12 h postconsumption. The addition of dark chocolate to the regimen may have increased the palatability of the diet. Participant feedback showed a 90% approval rating for the overall diet, indicating that it was well tolerated.

There was a trend towards greater lowering in SBP within the high-polyphenol group compared with the low-polyphenol group (mean change: −9.1±12.4 mm Hg vs −4.8±8.7 mm Hg respectively, p=0.059) on between-group analysis. Both SBP and diastolic BP decreased significantly on within-group analysis. However, the decrease in BP in both active and control groups may represent ‘regression to the mean’, a phenomenon that has been described in previous BP studies. Few polyphenol dietary intervention trials have assessed SBP. Previous calculations estimate that 115 participants would be required per group to detect a 5 mm Hg change in SBP with 90% power; therefore, this study may have been underpowered to detect a difference in SBP between groups, and a type II error is possible.

Between-group testing demonstrated a significantly greater reduction in total cholesterol (p=0.042) and a trend for greater
 decrease in LDL (p=0.063) in the high-polyphenol group compared with the low-polyphenol group. To put this into a clinical context, the change postintervention in LDL in high-polyphenol group in the PPhIT study equated to a 4.3% decrease in LDL concentrations, which, based on published data, would equate to a reduction in CVD mortality of approximately 4%.28

In contrast to the PPhIT study, most polyphenol studies have used single food interventions. Combining different polyphenol-rich foods may provide a cumulative increase in benefit due to the synergistic effect of several bioactive compounds. Potential mechanisms for the beneficial effects of polyphenols include their antioxidant and vasodilator functions, their ability to alter the expression of endothelial nitric oxide synthase and their ability to induce production of other endogenous vasodilators. However, many other cardiovascular benefits may exist, as described in recent reviews.29 30 The participants in the PPhIT study were free-living and allowed to make their own choices of type of F&V to be consumed. They also had hypertension and other cardiovascular risk factors. The results, therefore, are more relevant to ‘real-life’ than studies involving inpatient admission or supervised meals.

A concerted effort was made to keep other lifestyle variables constant during the study, reflected by static BMI and activity levels. However, in free-living individuals it is impossible to control for all variables in lifestyle. Due to budget and time constraints the PPhIT study was unable to use a factorial design to allow examination of the specific effect of berries and dark chocolate over and above increasing F&V intake alone. As such this study cannot conclusively state whether polyphenols or other bioactive components within these foods, such as carotenoids or vitamin C, working in isolation or synergistically, have led to the improvement in the primary endpoint. Future work could include comparison between low and high F&V versus high-polyphenol diets to definitively test the hypothesis that a greater improvement in FBF responses to ACh can be achieved with specific inclusion of polyphenol-rich foods, compared with an F&V-rich diet alone.

CONCLUSIONS

Increasing intake of polyphenol-rich foods, in the form of F&V, berries and dark chocolate, for 8 weeks resulted in a significant improvement in endothelium-dependent vasodilation in hypertensive participants. This study suggests that a well-tolerated polyphenol-rich diet could have a positive effect on microvascular function and cardiovascular risk.

Key messages

What is already known on this subject?

Previous epidemiological and intervention study evidence suggests that increasing fruit and vegetable consumption improves cardiovascular disease risk. More specifically, observational evidence to date indicates that polyphenol-rich foods, in particular berries and dark chocolate, may influence cardiovascular disease risk. However, there are few polyphenol-specific dietary intervention studies of sufficiently robust design that assess the effect of polyphenol-rich foods on microvascular function.

What might this study add?

Our group conducted a randomised control trial and found that increasing intake of polyphenol-rich foods, in the form of fruit and vegetables (including berries) and dark chocolate, for 8 weeks resulted in a significant improvement in endothelium-dependent vasodilation in hypertensive participants.

How might this impact on clinical practice?

This study suggests that a well-tolerated polyphenol-rich diet through the simple addition of berries and dark chocolate could have a positive effect on microvascular function and cardiovascular risk.

REFERENCES

13. ESH/ESC. 2013 ESH/ESC guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society


